With the rapidly increasing volume of clinical and scientific data, and hundreds of drugs currently in clinical trials, the task of interpreting molecular test results has become increasingly challenging.
QCI Precision Insights provides scalable, cost-effective genomic clinical decision support that delivers concise oncologist-reviewed evidence for each biomarker in the context of the cancer sub-type and available therapeutics matched by country.
QCI Precision Insight’s team of experts has interpreted more than 190,000 tumor samples. With this service, you can improve test turnaround time by 85-90% without the need for extra staffing.
Molecular pathology labs in Europe can now leverage QCI Precision Insights. The service now includes European Society for Medical Oncology (ESMO) guidelines, European LeukemiaNet (ELN) recommendations, and European Medicines Agency (EMA) approved oncology drugs.
Send your variants to QCI Precision Insights and receive expert-curated interpretation content in minutes
Submit your variant calling files (VCFs) and receive customized, oncologist-reviewed, variant-specific content within minutes.
Deliver reports with expert summaries of the latest biological, diagnostic, prognostic, and therapeutic evidence in context of the tumor profile, treatment, and regional clinical trials.
For rare or novel variants, enlist QIAGEN’s expert MD and PhD variant scientist team to perform the in-depth research, curation and interpretation for you.
Molecularly relevant treatment options
Deliver patient-specific reports comprising a filtered list of the patient’s actionable variants with respect to potential treatment options.
Minimize risk with identified potential interactions with drug sensitivity, resistance, or implications.
Professional guideline levels of evidence
Ensure a more consistent report format that clearly conveys the degree of importance with AMP/ASCO/CAP (United States) and ESMO (Europe) levels of evidence for variant classification.
Clinical trials by clinical significance and geographic specificity
Provide the most relevant treatment strategies, inclusive of molecularly and country-specific relevant clinical trials.
To accelerate test turnaround times and ensure accurate reporting, Quest partnered with QIAGEN Precision Insights to provide expert interpretation of its LeukoVantage assay, a NGS test designed specifically for detecting clinically relevant variants in myeloid malignancies.
Request a consultation with a QCI Precision Insights expert to learn more about the service and how you can start sending your test results today.
Clinical decision support software enabling faster test turnaround times and higher confidence reporting for any indication on your sequencing platform
Leverage the benefits of automation and expert support to improve test turnaround times and clinical reporting capabilities
Solve more cases faster, with data you can trust using HGMD Professional, the de facto standard resource for identifying inherited disease-causing mutations